evidence: Data on the efficacy of hydroxychloroquine or lopinavir-ritonavir for the treatment of high-risk outpatients with COVID-19 in developing countries are needed. [...] Given the DSMB decision, based on the Brazilian data confirming a lack of clinical benefits for hydroxychloroquine and lopinavir-ritonavir for outpatient treatment of patients with COVID-19, the enrollment in the United States and South Africa for these interventions has been discontinued. Other agents are rapidly being screened and developed for SARS-CoV-2 infection and can be incorporated into this master protocol for an outpatient platform trial as additional groups. The flexible platform trial design allows additional agents to be added and tested with standardized eligibility criteria, outcomes, and measurements. If an intervention is shown to be effective, this design allows the replacement of the placebo group with the effective intervention as the comparator. [...] M, et al; BCN PEP-CoV-2 RESEARCH GROUP. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial.